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during chemoradiation and further models to account for the 
effect of synchronous chemotherapy should be investigated.  
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Purpose or Objective: Cervical lymph node dissection for 
laryngeal cancer patients without clinical and radiologic 
evidence of regional metastasis (N0) is controversial. Aim of 
our study was to validate sentinel lymph node biopsy (SLNB) 
procedure and evaluate its applicability in early T1-2 N0 
laryngeal SCC. 
 
Material and Methods: A prospective study conducted at the 
Lithuanian University of Health Sciences Hospital, with the 
permission of institutional review board. Inclusion period 
2010 – 2013y. Patients with histologically confirmed laryngeal 
SCC T1-2, N0 were involved. Two phase design: validation 
phase - SLNB and selective neck dissection (SND) were 
performed simultaneously; application phase - SND was 
performed according to SLNB outcome. The end points for 
SLNB validation phase: sensitivity, specificity, negative-
predictive value (NPV). Patients from both phases were 
followed-up after treatment and compared for recurrence-
free survival (RFS). Sentinel lymph nodes (SLN) were located 
by 99mTc lymphoscintigraphy and gamma probe. Pathological 
evaluation included hematoxylin and eosin staining and 
immunohistochemistry. Statistical analysis was performed by 
using SPSS® v20.0, Clinical Calculator 1, ©Richard Lowry 
2001-2015.The Pearson X2 was used for categorical data. 
Significant p-value <0.05. RFS was investigated performing a 
log-rank test. 
 
Results: Clinicopathological features presented in table 1. In 
SLNB validation period we involved 16 pts. The mean number 
of SLNs per patient was 2.3. Four patients had positive SLN, 
no false positive results found. 12 pts had negative SLN, one 
of them had positive SND histological findings. The 
prevalence of positive lymph nodes was 0.31 (95% CI 0.12-
0.58), overall sensitivity was 0.8 (95% CI 0.29-0.98), 
specificity was 1 (95% CI 0.67-1). NPV of SLNB equal to 0.91 
(95% CI 0.59-0.99). During whole study period 46 pts were 
involved. The median of SLN removed per patient was 2.2. 
The total neck control rate was 87% and did not differ 
between validation and application groups (p=0.4). In a mean 
follow up period of 24 months, mean RFS time for validation 
group was 42 months (95%CI 37.36-48.28) vs 40 months in 
application group (95%CI 32.02-48.13), with no significant 
difference (p=0.43). 
 
Conclusion: More comprehensive study with a larger group of 
patients and longer follow-up is needed in order to confirm 
SLNB applicability, however preliminary data revealed SLNB 
as sensitive and specific with no negative influence on 
recurrence-free survival.  
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Purpose or Objective: Various methods have been described 
to delineate the oral mucosa organ at risk (OAR). Due to 
uncertainty in the literature, the purpose of this study was to 
examine whether dose delivered to two versions of this OAR 
correlated to the duration of acute grade 3 mucositis in 
patients with oropharyngeal carcinoma treated with intensity 
modulated radiotherapy (IMRT). 
 
Material and Methods: 66 patients previously treated with 
IMRT (55GY in 20 fractions over 25 days to the high dose 
volume; 46 in 20 fractions to areas at risk of harbouring 
microscopic disease) and synchronous carboplatin or 
cetuximab were included in this study. The duration of 
CTCAE version (v) 3 grade 3 mucositis (G3M) and the duration 
of strong opiate use (a surrogate for CTCAE v4 G3M) had been 
prospectively recorded at the time of treatment. Standard 
and modified oral mucosa OARs were contoured and the 
following dose parameters derived: mean dose, V55, V50, 
V45, V40 and V30. 
Spearman’s correlation was used to investigate for a 
relationship between the duration of v3 G3M or strong opiate 
use and these dose parameters for each OAR and 6 additional 
patient factors: pre-radiotherapy haemoglobin, weight, age, 
smoking status, use of neo-adjuvant chemotherapy and 
synchronous chemotherapy (carboplatin v. cetuximab). 
 
Results: No statistically significant correlation of v3 G3M or 
duration of strong opiate use was noted with the tested 
parameters with the exception of a trend towards 
significance with pre-treatment weight (p=0.053). Duration 
of opiate use was found be to be approximately proportional 
to pre-treatment weight. 
 
Conclusion: This study failed to show a relationship between 
dose to the standard or modified oral mucosa OAR and the 
duration of CTCAE v3 G3M or duration of opiate use in 
patients undergoing IMRT for oropharyngeal cancer. Further 
work is required to test these models with particle therapy 
where lower dose distributions to oral mucosa may be 
achievable. The utility of CTCAE v4 G3M as an endpoint if 
confirmed in larger studies to be related to pre-treatment 
weight is questioned by this study. 
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Purpose or Objective: Unilateral neck radiotherapy is 
considered a standard treatment for well-lateralized 
squamous cell carcinomas of the tonsil related to a HPV 
infection. Well-lateralized tumours are defined as T0-T2 N0-
N2b M0 and not invading the base of tongue nor extending 
more than 1 cm into the soft palate. We performed a 
retrospective review aiming to assess the risk of a 
contralateral neck recurrence in this group of patients with a 
particular focus on those diagnosed with N2b disease. 
 
Material and Methods: Fifty patients with T0-T3 N0-2b M0 
disease (only two had T3 tumours) were treated with 
unilateral 3DCRT between February 2004 and July 2011. All 
50 patients had p16-positive tumours. They all received 
chemotherapy (concomitant, induction or both) apart from 
two. Twenty-six patients presented with N2b disease. Median 
follow-up was 54 months. 
 
Results: Four patients relapsed in the contralateral neck with 
no evidence of local or ipsilateral regional failure; one with 
recurrent contralateral retropharyngeal nodes and the rest 
with contralateral level II-IV nodes. Median time to a 
contralateral recurrence was 32 months (range, 22-47 
months). All 4 patients initially presented with T1 N2b M0 
disease. Upon recurrence, 2 of these patients were treated 
with a salvage neck dissection followed by chemoradiation 
and 2 with re-irradiation. Both re-irradiation patients 
developed a further recurrence and one of them died of his 
